EGFR and hepatocellular carcinoma: EGFR knockdown or treatment with Erlotinib abrogated recombinant SPINK1-induced self-renewal and chemoresistance properties (Fig. 6c, e, Supplementary Fig. S5b, d), suggesting SPINK1 regulates HCC through an EGFR axis.